Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

134.07USD
1:23pm EDT
Change (% chg)

$1.59 (+1.20%)
Prev Close
$132.48
Open
$133.00
Day's High
$134.24
Day's Low
$132.67
Volume
650,513
Avg. Vol
1,912,495
52-wk High
$148.32
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.68
Market Cap(Mil.): $349,911.91
Shares Outstanding(Mil.): 2,682.76
Dividend: 0.90
Yield (%): 2.72

Financials

  JNJ.N Industry Sector
P/E (TTM): 24.18 28.11 30.17
EPS (TTM): 5.48 -- --
ROI: 11.89 12.95 12.67
ROE: 22.21 14.96 14.86

Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis. | Video

3:37am EDT

UPDATE 2-Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK, Aug 16 The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis.

Aug 16 2018

J&J loses bid to dismiss Pfizer antitrust case over Remicade

A federal judge on Friday rejected Johnson & Johnson's bid to dismiss a lawsuit by Pfizer Inc claiming that the drugmaker had engaged in an anticompetitive scheme to shield its blockbuster rheumatoid arthritis drug Remicade from competition.

Aug 10 2018

Judge cut $15 million from J&J pelvic mesh verdict

A federal judge has ruled that a $35 million jury award to an Indiana woman who said she suffered injuries due to a pelvic mesh device manufactured by Johnson & Johnson's Ethicon unit must be reduced by $15 million.

Aug 09 2018

UPDATE 1-Drug distributor Cardinal's profit beats on pharma unit strength

Aug 6 U.S. drug distributor Cardinal Health Inc beat analyst estimates for adjusted fourth-quarter profit on Monday, supported by higher sales in its pharmaceutical and medical devices businesses.

Aug 06 2018

U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict

Wall Street is trying to figure out whether the U.S. insurance industry will bear any costs from a record $4.69 billion judgment against Johnson & Johnson awarded to customers and their families who claimed that asbestos-contaminated talc caused ovarian cancer.

Jul 31 2018

CORRECTED-U.S. insurers grilled on exposure to $4.7 bln J&J talc verdict

July 31 Wall Street is trying to figure out whether the U.S. insurance industry will bear any costs from a record $4.69 billion judgment against Johnson & Johnson awarded to customers and their families who claimed that asbestos-contaminated talc caused ovarian cancer.

Jul 31 2018

Pfizer CEO expects Trump to eliminate drug rebates

Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers. | Video

Jul 31 2018

UPDATE 4-Pfizer CEO expects Trump to eliminate drug rebates

July 31 Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers.

Jul 31 2018

Bayer hits back at new Netflix medical device documentary

NEW YORK Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety.

Jul 27 2018

Earnings vs. Estimates